Tavaborole

FDA Approved: * May 7, 2021
Pharm Company: * TARO PHARMA USA INC
Category: Antifungal

Tavaborole, sold under the brand name Kerydin, is a topical antifungal medication for the treatment of onychomycosis, a fungal infection of the nail and nail bed. Tavaborole was approved by the US FDA in July 2014.[1] The medication inhibits an essential fungal enzyme, leucyl-tRNA synthetase, that is required for protein synthesis. The inhibition of protein synthesis leads to termination of cell growth and then cell death, eliminating the fungal infection. Contents 1 Medical... [wikipedia]

* May have multiple approval dates, manufacturers, or labelers.

Dosage List

Tavaborole 43.5 mg/ml Topical Solution
NDC: 0574-0157
Labeler:
Paddock Laboratories, LLC.
Tavaborole 43.5 mg/ml Topical Solution
NDC: 21922-020
Labeler:
Encube Ethicals Private Limited
Tavaborole 43.5 mg/ml Topical Solution
NDC: 51672-1397
Labeler:
Taro Pharmaceuticals U.S.a., Inc.
Tavaborole 43.5 mg/ml Topical Solution
NDC: 51862-690
Labeler:
Mayne Pharma Inc.
Tavaborole 43.5 mg/ml Topical Solution
NDC: 62332-467
Labeler:
Alembic Pharmaceuticals, Inc.
Tavaborole 43.5 mg/ml Topical Solution
NDC: 63629-8704
Labeler:
Bryant Ranch Prepack
Tavaborole 43.5 mg/ml Topical Solution
NDC: 68180-958
Labeler:
Lupin Pharmaceuticals, Inc.
Tavaborole 43.5 mg/ml Topical Solution
NDC: 69097-686
Labeler:
Cipla USA Inc.
Tavaborole 43.5 mg/ml Topical Solution
NDC: 69238-1657
Labeler:
Amneal Pharmaceuticals Ny LLC

Related Brands

Drugs with the same active ingredients